170 related articles for article (PubMed ID: 38342622)
1. Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex.
Jiang H; Wang Y; Wen D; Yu R; Esa SS; Lv K; Feng Q; Liu J; Li F; He L; Di X; Zhang S
Adv Sci (Weinh); 2024 Apr; 11(15):e2306623. PubMed ID: 38342622
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of liver cancer cell-secreted exosomal PSMA5 controls macrophage polarization to restrain cancer progression by blocking JAK2/STAT3 signaling.
Xie S; Li X; Yan J; Yu H; Chen S; Chen K
Immun Inflamm Dis; 2024 Feb; 12(2):e1146. PubMed ID: 38415977
[TBL] [Abstract][Full Text] [Related]
3. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Chen J; Sun S; Li H; Cai X; Wan C
Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
[TBL] [Abstract][Full Text] [Related]
4. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
5. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
[TBL] [Abstract][Full Text] [Related]
6. Curcumin Inhibits the Growth of Hepatocellular Carcinoma via the MARCH1-mediated Modulation of JAK2/STAT3 Signaling.
Su J; Liu X; Zhao X; Ma H; Jiang Y; Wang X; Wang P; Zhao M; Hu X
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38243928
[TBL] [Abstract][Full Text] [Related]
7. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
[TBL] [Abstract][Full Text] [Related]
8. MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma.
Xiao Y; Li Y; Shi D; Wang X; Dai S; Yang M; Kong L; Chen B; Huang X; Lin C; Liao W; Xu B; Chen X; Wang L; Chen X; Ouyang Y; Liu G; Li H; Song L
Cancer Res; 2022 Nov; 82(22):4191-4205. PubMed ID: 36112698
[TBL] [Abstract][Full Text] [Related]
9. Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production.
Li J; Ge M; Deng P; Wu X; Shi L; Yang Y
Immunopharmacol Immunotoxicol; 2024 Feb; 46(1):40-48. PubMed ID: 37671837
[TBL] [Abstract][Full Text] [Related]
10. Icaritin-Induced FAM99A Affects GLUT1-Mediated Glycolysis
Zheng X; Gou Y; Jiang Z; Yang A; Yang Z; Qin S
Front Oncol; 2021; 11():740557. PubMed ID: 34765550
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway.
Hu X; Jiao F; Zhang L; Jiang Y
Front Pharmacol; 2021; 12():654986. PubMed ID: 33995073
[TBL] [Abstract][Full Text] [Related]
12. Cepharanthine suppresses proliferation and metastasis and enhances apoptosis by regulating JAK2/Stat3 pathway in hepatocellular carcinoma.
Liang Y; Li J; Xu H; Pang M; Hu C; Weng X; Xie W
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):94-100. PubMed ID: 38279472
[TBL] [Abstract][Full Text] [Related]
13. LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells.
Liu Y; Chen L; Yuan H; Guo S; Wu G
Onco Targets Ther; 2020; 13():1145-1157. PubMed ID: 32103983
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma.
Li CJ; Tsai HW; Chen YL; Wang CI; Lin YH; Chu PM; Chi HC; Huang YC; Chen CY
J Hepatocell Carcinoma; 2023; 10():123-138. PubMed ID: 36741246
[TBL] [Abstract][Full Text] [Related]
16. Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway.
Wu Y; Yuan T; Wang WW; Ge PL; Gao ZQ; Zhang G; Tang Z; Dang XW; Zhao YF; Zhang JY; Jiang GZ
Cell Physiol Biochem; 2018; 51(1):301-314. PubMed ID: 30453302
[TBL] [Abstract][Full Text] [Related]
17. A curcumin analog GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circular RNA zinc finger protein 83/microRNA-324-5p/cyclin-dependent kinase 16 axis.
Zhao JA; Nie W; Dong L; Liu W; Wei W
J Gastroenterol Hepatol; 2021 Oct; 36(10):2967-2977. PubMed ID: 33982329
[TBL] [Abstract][Full Text] [Related]
18. Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375.
Li L; Xiao C; He K; Xiang G
IUBMB Life; 2021 Sep; 73(9):1153-1165. PubMed ID: 34148288
[TBL] [Abstract][Full Text] [Related]
19. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway.
Zhao Z; Song J; Tang B; Fang S; Zhang D; Zheng L; Wu F; Gao Y; Chen C; Hu X; Weng Q; Yang Y; Tu J; Ji J
J Exp Clin Cancer Res; 2020 Nov; 39(1):259. PubMed ID: 33234142
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
